MedTrace Logo

Sorafenib for Hepatopulmonary Syndrome

NCT02021929 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-04-25

Study results available
· View outcomes & findings →

Summary

The main purpose of this clinical trial is to determine the safety and effects of the study drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels.

Conditions

  • Hepatopulmonary Syndrome

Interventions

DRUG

Sorafenib

Sorafenib is a kinase inhibitor indicated for the treatment of: * Unresectable hepatocellular carcinoma * Advanced renal cell carcinoma * Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Steven M Kawut, MD, MS · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02021929 on ClinicalTrials.gov